摘要:
The present invention provides a compound of the formula (I) or (II), wherein R1 is H, alkyl, alkenyl or aryl, R2 is H, alkyl, alkenyl or aryl, R3 is H, alkyl, alkenyl or aryl, R?4 and R4-R8¿ are independently R?10, C(O)R10¿ or SO¿2R?10, wherein R10 is H, alkyl, alkenyl or aryl, and R?9 is R9a, C(O)R9a¿ or SO¿2R?9a, wherein R9a is H, alkyl, alkenyl or aryl. R9a can be unsubstituted or substituted with one or more oxo(=O), OR9b, OC(O)R9b, OSO2R?9b, NHR9b¿, NHC(O)R9b and NHSO¿2R?9b groups. R9b is H, alkyl, alkenyl, or aryl. R9b can be unsubstituted or substituted with one or more groups such as oxo(=O), OR9c, CO2R9c, CO2R9c and OC(O)R9c. R9c is H, or a unsubstituted or substituted alkyl, alkenyl or aryl. The present invention further provides a composition comprising at least one compound of the present invention and a pharmaceutically acceptable carrier, alone or in combination with at least one additional active agent. The present invention further provides a method of treating a condition treatable by the inhibition of vacuolar-type (H+)-ATPase and a method of treating cancer.
摘要:
A substantially purified compound of the formula: a composition comprising a therapeutically effective amount of at least one compound of the formula, alone or in combination with at least one additional therapeutic agent, and methods of preventing or treating cancer and a condition treatable by the inhibition of vacuolar-type (H+)-ATPase